Bedaquiline is a diarylquinoline antitubercular agent that selectively inhibits mycobacterial ATP synthase, providing a critical treatment option for multidrug-resistant tuberculosis. Simson Pharma's Bedaquiline reference standard and impurities support the stringent QC this last-resort antitubercular therapy demands.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Bedaquiline Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.